Abzu and Contera Pharma expand strategic partnership - #BHHMembersInitiatives
Home News Abzu and Contera Pharma expand strategic partnership - #BHHMembersInitiatives

Abzu and Contera Pharma expand strategic partnership - #BHHMembersInitiatives

APRIL 19, 2023 Members' News

BHH member Abzu® and Contera Pharma expand their strategic partnership to add drug-target identification to their seminal RNA- and siRNAs therapeutic design platform. Contera Pharma is a Danish biotech company developing innovative small-molecule and RNA-based therapeutics to address neurological disorders.

Their unique R&D model integrates their team of experienced neuroscience drug hunters with cutting-edge technology, like Abzu’s proprietary discovery engine, the QLattice®, to develop precision medicines. Abzu’s QLattice, a new class of explainable artificial intelligence with recently-patented technology, accelerates scientists’ exploration and understanding of relationships in data. Abzu and Contera Pharma initially collaborated in July 2021 to incorporate the QLattice into an RNA therapeutic design application.

The application designs RNA therapeutics through parallel hypotheses testing of drug targets and individual antisense oligonucleotide (ASO) drug properties. After seeing accelerated progress on two undisclosed therapeutics currently in preclinical testing, Abzu and Contera Pharma agreed to expand their strategic partnership, adding siRNAs and target identification to the platform. "Our expanded strategic partnership is based on a three-pronged approach to strengthen our drug discovery platform: First, we run ASO drug design by automation; second, we will add siRNAs as an RNA therapeutic modality; and third, we identify novel targets with Abzu’s explainable artificial intelligence," says Kenneth Christensen, Chief Scientific Officer of Contera Pharma.

"We want to turbocharge the development of RNA medicines," says Martin Kerr, Head of Business Development and Pharma Partnerships at Abzu. "With Contera Pharma, we’re designing and testing RNA medicines to multiple targets — all at once — which means that we’re breaking new ground faster than anyone else."

Combined, this expanded partnership advances the companies vision to accelerate the drug discovery process by deepening the disease and disease-target understanding and at the same time accelerating rational drug design.

Read more HERE.  

November 20, 2026 Members' News
Derm2check Breaks Away From One-Sided AI Skin Apps
Dutch platform combines a free AI skin check with an international network of dermatologists, from first suspicion to treatment Derm2check is the result of a pilot phase of about a year, during which broad experience was built up worldwide in digital dermatological care. That practical experience has now been incorporated into a fully renewed platform, which combines AI technology with a free AI Check for users.
Read more
November 20, 2026 Members' News
SMED Clinical Research joins the Barcelona & Madrid Health Hub
Joining Barcelona & Madrid Health Hub marks an important step for SMED Clinical Research as the company continues to strengthen its presence within the healthcare and life sciences ecosystem. It creates new opportunities to stay close to innovation, collaborate with leading organisations, and better understand the evolving needs of sponsors, clinical sites and the patients they serve.
Read more
November 19, 2026 Members' News
Partner Insights 2026: Technology, Innovation and Collaboration in Life Sciences
Ambit Iberia has launched Partner Insights 2026, the new edition of its annual magazine bringing together the perspectives of 13 technology partners on the trends, challenges and opportunities shaping the future of the Life Sciences industry.
Read more
November 19, 2026 Members' News
Artificial Intelligence comes to informed consent to answer patients’ questions before surgery
Informed consent is a routine process in any hospital, but its management continues to generate costs, administrative workload and traceability issues when carried out on paper. To address these challenges, ASHO has developed a new end-to-end informed consent management platform that digitizes the entire process and gives patients a more active role, allowing them to access the information in advance, resolve their questions before signing and arrive at surgery with a better understanding of the procedure.
Read more
November 18, 2026 Members' News
Corporate Nutrition for Every Type of Work. The Great Blind Spot in Workplace Wellness
Do we really take care of all the factors that influence team well-being? In recent years, companies have made progress in mental health, work-life balance, flexibility, and creating healthier work environments. However, there is one element that often remains outside the strategy or is treated in a merely informative way: nutrition during the workday.
Read more
November 16, 2026 Members' News
M2H brings exercise prescription into Primary Care: doctors and exercise specialists, finally on a single digital layer
The Barcelona-based healthtech startup, a new member of Barcelona & Madrid Health Hub, connects family doctors and Physical Exercise Specialists within the same clinical workflow, keeping full patient traceability.
Read more
November 13, 2026 Members' News
Fund It, Build It, Certify It: A MedTech Startup's Roadmap to Market
Most MedTech startups don't stall because the technology fails. They stall because funding and regulation were planned separately. Under MDR, compliance is not the last step before submission. It shapes your product and company decisions from day one. And investors know it: before a Series A or B, they expect a credible regulatory strategy, not just a promising prototype. That's why, QbD Group and Capital Cell teamed up, to bring both sides together in one free webinar live session.
Read more
November 13, 2026 Members' News
The Ultimate Guide for Choosing an Enterprise CMS
In strictly regulated industries like pharmaceutical and health insurance, delivering seamless, compliant digital experiences—from patient portals to provider resources—is critical. Magnolia is a leading composable Digital Experience Platform (DXP) trusted by healthcare and global enterprise giants like Sanofi and Generali. By centralizing websites, portals, and apps into one intuitive, open platform, Magnolia's CMS empowers IT teams to build freely and marketing teams to launch faster—all while protecting brand integrity and compliance.
Read more
November 12, 2026 Members' News
Health Tech Enterprise launches half-price UK market entry offer for Barcelona & Madrid Health Hub members
Health Tech Enterprise introduces an exclusive UK Market Entry Pathfinder offer for Barcelona & Madrid Health Hub members, helping MedTech companies assess their readiness for UK expansion and receive an evidence-based market entry recommendation within 21 days, with preferential member pricing available until 31 December 2026.
Read more
November 12, 2026 Members' News
Your Next Innovation May Already Exist
Connecting business challenges with scientific knowledge
Read more